Tepeoglu Merih, Borcek Pelin, Ozen Ozlem, Altinors Nur
Baskent University, Faculty of Medicine, Department of Pathology, Ankara, Turkey.
Turk Neurosurg. 2019;29(5):778-784. doi: 10.5137/1019-5149.JTN.27333-19.1.
To evaluate the frequency and prognostic significance of microsatellite instability (MSI) in patients with glioblastoma (GBM), an immunohistochemical analysis of mismatch repair (MMR) proteins was performed.
A total of 71 patients with GBM who underwent surgery between 2011 and 2019, were included in the study. MMR protein expression was examined using immunohistochemistical analysis of tumor tissue samples; the association between the MMR status and clinicopathological findings was evaluated.
Immunohistochemical analysis revealed expressions of MLH1, MSH2, MSH6, and PMS2 proteins in 67 (94.4%), 65 (91.5%), 67 (94.4%), and 64 (90.1%) patients, respectively. Among the 71 patients, 64 (90.1%) expressing all MMR proteins were considered microsatellite stable (MSS), and 7 (9.9%) patients showing loss of at least one of the MMR proteins were considered to show MSI. Tumor recurrence was noted in 25 (39.1%) patients in the MSS GBM group, and 4 (57.1%) patients in the MSI GBM group (p=0.433). The overall median survival was 30.65 ± 5.1 and 10.71 ± 5.2 months in the MSS GBM and MSI GBM groups, respectively (p=0.059).
The results of this study showed no significant relationships between MMR protein expression and recurrence rates or overall survival in patients with GBM.
为评估胶质母细胞瘤（GBM）患者中微卫星不稳定性（MSI）的频率及预后意义，对错配修复（MMR）蛋白进行了免疫组化分析。
本研究纳入了2011年至2019年间接受手术的71例GBM患者。采用肿瘤组织样本免疫组化分析检测MMR蛋白表达；评估MMR状态与临床病理结果之间的关联。
免疫组化分析显示，MLH1、MSH2、MSH6和PMS2蛋白分别在67例（94.4%）、65例（91.5%）、67例（94.4%）和64例（90.1%）患者中表达。在这71例患者中，64例（90.1%）表达所有MMR蛋白的患者被认为是微卫星稳定（MSS），7例（9.9%）至少有1种MMR蛋白缺失的患者被认为表现为MSI。MSS GBM组25例（39.1%）患者出现肿瘤复发，MSI GBM组4例（57.1%）患者出现肿瘤复发（p = 0.433）。MSS GBM组和MSI GBM组的总中位生存期分别为30.65±5.1个月和10.71±5.2个月（p = 0.059）。
本研究结果显示，GBM患者的MMR蛋白表达与复发率或总生存期之间无显著相关性。
